Serotonin (5-HT) and oxytocin (OXT) are two neuromodulators involved in human affect and sociality and in disorders like depression and autism. We asked whether these chemical messengers interact in the regulation of emotion-based behavior by administering OXT or placebo to 24 healthy subjects and mapping cerebral 5-HT system by using 2′-methoxyphenyl-(N-2′-pyridinyl)-p-[ ]MPPF nondisplaceable binding potential (BP ND ) in the dorsal raphe nucleus (DRN), the core area of 5-HT synthesis, and in the amygdala/hippocampal complex, insula, and orbitofrontal cortex. Importantly, the amygdala appears central in the regulation of 5-HT by OXT: [ 18 F]MPPF BP ND changes in the DRN correlated with changes in right amygdala, which were in turn correlated with changes in hippocampus, insula, subgenual, and orbitofrontal cortex, a circuit implicated in the control of stress, mood, and social behaviors. OXT administration is known to inhibit amygdala activity and results in a decrease of anxiety, whereas high amygdala activity and 5-HT dysregulation have been associated with increased anxiety. The present study reveals a previously unidentified form of interaction between these two systems in the human brain, i.e., the role of OXT in the inhibitory regulation of 5-HT signaling, which could lead to novel therapeutic strategies for mental disorders. B rain chemistry strongly influences our behavior. Among neuromodulators, serotonin (5-HT) and oxytocin (OXT) are important for the regulation and expression of several behaviors such as human affects and socialization. Both systems have been implicated in the control of stress, anxiety, and social cooperation (1, 2). Moreover, their dysfunction is associated with major psychiatric disorders such as depression (3, 4) and autism (5,6). Recent animal studies demonstrated that specific anatomical links exist between these two molecules. Serotonergic fibers originating from the dorsal and medial raphe nuclei of the brainstem project toward magnocellular neurons in the paraventricular and supraoptic nuclei of the hypothalamus, where OXT is released (7). In this region, 5-HT fibers overlap and follow the distribution of OXT cells (8). Importantly, in the raphe nuclei, the core area of 5-HT synthesis, serotonergic neurons display OXT receptors and OXT modulates the release of 5-HT (9). Recent results have also shown that administration of OXT during the postnatal period increases the length of serotonergic axons in the hypothalamus and in the amygdala (10). In return, 5-HT is able to modulate OXT release while interacting with different 5-HT receptors in the hypothalamus (11). Also, the administration of fenfluramine, a serotonergic agonist, to healthy subjects increases plasma OXT level (12). These findings indicate that OXT and 5-HT share anatomical substrates, which may constitute a functional interface in the regulation of emotionbased behaviors. Behaviorally, OXT and 5-HT modulate reactions to social contexts and threatening stimuli in humans and animals (13,14). For instance, oversens...